Core Viewpoint - Green Biological Technology Co., Ltd. (hereinafter referred to as Green Biological) is making another attempt to go public (IPO) after two previous unsuccessful attempts, amidst a renewed wave of IPOs in the cosmetics raw material sector [1][2][5]. Company Overview - Green Biological was established in December 1999, focusing on the research, production, and sales of bio-based and fully synthetic fragrances. Its product lines include turpentine, cedarwood oil, and various synthetic fragrances [2][5]. - The company is one of the largest suppliers of methyl cedryl ketone in China, with significant usage in household and high-end perfume products [2][5]. - The founder, Lu Wencong, holds 27.11% of the company's shares, and his daughter holds an additional 9%, making them the actual controllers of the company [6][7]. IPO Attempts - Green Biological's first IPO attempt began in 2018, but it was halted in early 2021 due to issues related to information disclosure and a significant expected drop in net profit [5][9]. - The second attempt in June 2023 also ended in withdrawal due to similar concerns raised by the Shenzhen Stock Exchange regarding environmental issues and innovation capabilities [5][9]. Financial Performance - The company has shown strong revenue growth, with revenues of 594 million, 631 million, and 735 million yuan from 2021 to 2023, representing growth rates of 6.23%, 16.48%, and a compound annual growth rate of 10.92% [9][10]. - Net profits for the same period were 201.7 million yuan, with growth rates of 65.85% and 32.35% in 2022 and 2023, respectively, leading to a compound growth rate of 48.43% [9][10]. - As of the end of 2023, total assets reached 1.433 billion yuan, with a net profit of 92.92 million yuan and a return on equity of 20.65% [10][11]. Market Context - The cosmetics raw material market in China is projected to grow from 1147.80 billion yuan in 2019 to 1603.90 billion yuan by 2024, with a compound annual growth rate of 6.9% [14]. - The recent surge in IPOs among raw material suppliers is attributed to the booming cosmetics industry and favorable regulatory changes, including the establishment of the Beijing Stock Exchange and reforms in the Sci-Tech Innovation Board [15][16][17]. - Green Biological's export revenue has been significant, accounting for over 84% of its main business from 2021 to 2023, with major clients including Procter & Gamble and other international raw material suppliers [11][12].